Ahead of print
Case report
Published online: 2023-12-11

open access

Page views 192
Article views/downloads 75
Get Citation

Connect on Social Media

Connect on Social Media

Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports

Martyna Tyszka1, Letycja Róg1, Jolanta Małyszko2, Rafał Stec1

Abstract

The number of patients with end-stage renal disease requiring hemodialysis and diagnosed with various types of cancer is constantly growing, but guidelines on systemic treatment in this particular clinical scenario are lacking. Testicular cancer is a highly curable malignancy, but data on post-orchidectomy systemic treatment based on cisplatin in patients requiring hemodialysis are scarce. We present two cases of patients with testicular germ cell tumors (one intermediate-risk seminoma and one low-risk non-seminoma) treated with chemotherapy while on hemodialysis in our center. Furthermore, we discuss the appropriate doses of cytotoxic drugs and the timing of hemodialysis. 

Article available in PDF format

View PDF Download PDF file

References

  1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1): 7–11.
  2. Fischereder M. Cancer in patients on dialysis and after renal transplantation. Nephrol Dial Transplant. 2008; 23(8): 2457–2460.
  3. Wieliczko M, Pyrża M, Małyszko J. CANCER IN DIALYSIS PATIENTS. Wiad Lek. 2020; 73(9 cz. 2): 2068–2072.
  4. Pedrazzoli P, Silvestris N, Santoro A, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). ESMO Open. 2017; 2(3): e000167.
  5. Sandhu GAJ, Armstrong GE, O’Neill N. On behalf of the ADDIKD Guideline, Group. International consensus guideline on anticancer drug dosing in kidney dysfunction. eviQ, Cancer Institute NSW, St Leonards, Australia 2022.
  6. Giona S. The Epidemiology of Testicular Cancer. Urologic Cancers. 2022: 107–116.
  7. Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013; 24(2): 501–507.
  8. Funakoshi T, Horimatsu T, Nakamura M, et al. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open. 2018; 3(2): e000301.
  9. Froehner M, Passauer J, Schuler U, et al. Successful chemotherapy for advanced nonseminomatous germ-cell tumor in a patient undergoing chronic hemodialysis. J Clin Oncol. 2007; 25(10): 1282–1284.
  10. Méndez-Calderillo V, Nuñez-Saldaña G. Successful treatment of a patient with renal failure, treated with haemodialysis, and advanced ovarian germ cell tumour using modified cisplatin-based chemotherapy duplet. Ecancermedicalscience. 2022; 16: 1397.
  11. Kamizuru M, Iwata H, Terada T, et al. [Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. Nihon Hinyokika Gakkai Zasshi. 2000; 91(7-8): 599–603.
  12. Moore KJ, Snow S, Wood LA. Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis. Curr Oncol. 2022; 29(3): 1808–1812.
  13. Janus N, Thariat J, Boulanger H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010; 21(7): 1395–1403.